



(51) International Patent Classification:

C07D 487/10 (2006.01) *A61P 29/00* (2006.01)
A61K 31/407 (2006.01) *A61P 25/00* (2006.01)

(21) International Application Number:

PCT/GB2012/053233

(22) International Filing Date:

21 December 2012 (21.12.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/579,613 22 December 2011 (22.12.2011) US
1122113.2 22 December 2011 (22.12.2011) GB

(71) Applicant: **CONVERGENCE PHARMACEUTICALS LIMITED** [GB/GB]; 90 High Holborn, London WC1V 6XX (GB).

(72) Inventors: **WITTY, David R.**; c/o Convergence Pharmaceuticals Limited, Maia Building, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB).
MACPHERSON, David T.; c/o Convergence Pharmaceuticals Limited, Maia Building, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB).
GIBLIN, Gerard M.P.; c/o Convergence Pharmaceuticals Limited, Maia Building, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB).
STANWAY, Steven J.; c/o Convergence Pharmaceuticals Limited, Maia Building, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB).

(74) Agents: **GIBSON, Mark** et al.; Sagittarius IP, Three Globeside, Fieldhouse Lane, Marlow Buckinghamshire SL7 1HZ (GB).


(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: 2 - (PYRIDIN- 2YL) - 1, 7 -DIAZA-SPIRO [4.4] NONANE- 6 -ONE COMPOUND AS VOLTAGE-GATED SODIUM CHANNELS MODULATOR



(57) Abstract: The invention relates to spiro derivative of formula (I), to the use of said derivative in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivative and processes for its preparation.